Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
Advances in therapy for newly diagnosed multiple myeloma (NDMM) have improved survival, but relapse remains common, and treatment decisions are increasingly complex. Quadruplet regimens that include anti‑CD38 antibodies and next-generation proteasome inhibitors are transforming care for both patients who are eligible for transplant and those who are not, offering new opportunities along with important practical challenges.
In this CME‑certified hybrid symposium, internationally recognized experts present the latest evidence from landmark clinical trials and translate these findings into real‑world practice. Participants will receive practical guidance on assessing transplant eligibility, optimizing induction and maintenance therapy, and personalizing treatment while balancing efficacy, toxicity, and patient preferences. They will also learn strategies to manage adverse events and gain insight into emerging approaches, including cellular therapies, bispecific antibodies, and antibody drug conjugates.
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of multiple myeloma.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate disease- and patient-specific characteristics that contribute to assessment of transplant eligibility in patients with newly diagnosed multiple myeloma (NDMM)
- Incorporate efficacy and safety data from landmark clinical trials of novel therapeutic approaches into individualized treatment plans for patients with NDMM
- Tailor maintenance therapy strategies based on prior treatments, disease risk, and treatment response
- Provide evidence-based supportive care measures to prevent and manage treatment-related adverse events in patients with NDMM
Ajai Chari, MD
Professor, Medicine
Director, Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genetech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, Sanofi/Genzyme. Grant/ Research Funding: Janssen.
Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology Director, Myeloma Unit
University of Salamanca
Salamanca, Spain
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Johnson & Johnson, BMS, Amgen, Sanofi, GSK, Pfizer, Kite, Stemline-menarini, oncopeptides, Roche
Mohamad Mohty, MD, PhD
Professor of Hematology
Sorbonne University
Head, Clinical Hematology and Cellular Therapy Department
Saint-Antoine Hospital
Paris, France
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Astellas, Adaptive Biotechnologies, BMS, GSK, Pfizer, Takeda, Stemline, Maat, Sanofi, Novartis, Janssen. Grant/Research Funding: Sanofi, Novartis, Janssen.
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here